MedTrace Logo

Glucose Control In Hematopoetic Stem Cell Transplant

NCT00582036 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-04-20

Study results available
· View outcomes & findings →

Summary

To determine whether intensive glucose control results in improved mortality and reduced hospital stay length by performing a randomized trial of intensive glucose management (blood glucose goal 110 mg/dl) using continuous IV insulin and glucose vs. non-intensive glucose management (goal 200 mg/dl)

Conditions

Interventions

DRUG

Regular Insulin

Use of sliding scale insulin as per Appendix 1

DEVICE

Deployment of the MiniMed Paradigm monitoring device

Automated insulin delivery system

Sponsors & Collaborators

  • Oklahoma Center for the Advancement of Science and Technology

    collaborator OTHER

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • George Selby, MD · University of Oklahoma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00582036 on ClinicalTrials.gov